지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 244 - 252 (9page)
이용수
초록· 키워드
오류제보하기
BackgroundSystemic inflammatory response can be associated with the prognosis of diffuse large B cell lymphoma (DLBCL). We investigated the systemic factors significantly related to clinical outcome in relapsed/refractory DLBCL.MethodsIn 242 patients with DLBCL, several factors, including inflammatory markers were analyzed. We assessed for the correlation between the survivals [progression-free surviv-al (PFS) and overall survival (OS)] and prognostic factors. ResultsIn these patients, a high derived neutrophil/lymphocyte ratio (dNLR) (PFS, HR=2.452, P=0.002; OS, HR=2.542, P=0.005), high Glasgow Prognostic Score (GPS) (PFS, HR=2.435, P=0.002; OS, HR=2.621, P=0.002), and high NCCN-IPI (PFS, HR=2.836, P=0.003; OS, HR=2.928, P=0.003) were significantly associated with survival in multi-variate analysis. Moreover, we proposed a risk stratification model based on dNLR, GPS, and NCCN-IPI, thereby distributing patients into 4 risk groups. There were significant differences in survival among the 4 risk groups (PFS, P＜0.001; OS, P＜0.001). ConclusionIn conclusion, dNLR, GPS, and NCCN-IPI appear to be excellent prognostic parameters for survival in relapsed/refractory DLBCL.
목차
등록된 정보가 없습니다.
참고문헌 (31)
참고문헌 신청
Morton LM / 2006 / Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 / Blood 107:265~276
Sehn LH / 2005 / Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia / J Clin Oncol 23:5027~5033
Gisselbrecht C / 2010 / Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era / J Clin Oncol 28:4184~4190
Zhou Z / 2014 / An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era / Blood 123:837~842
Prochazka KT / 2018 / Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma / Br J Haematol 183:142~146
Sehn LH / 2005 / Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia / J Clin Oncol 23:5027~5033
Gisselbrecht C / 2010 / Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era / J Clin Oncol 28:4184~4190
Zhou Z / 2014 / An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era / Blood 123:837~842
Prochazka KT / 2018 / Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma / Br J Haematol 183:142~146
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
Cancer Research and Treatment
2021 .01
-
Prognostic implication of systemic inflammatory markers in young patients with resectable colorectal cancer
Annals of Surgical Treatment and Research
2021 .01
-
Adding MYC/BCL2 double expression to NCCN‑IPI may not improve prognostic value to an acceptable level
Blood Research
2024 .03
-
Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma
Journal of Pathology and Translational Medicine
2022 .01
-
Comparison of inflammation-based prognostic scores as predictors of survival outcomes in patients with germ cell tumors
Investigative and Clinical Urology
2021 .01
-
Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma
Blood Research
2017 .01
-
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Cancer Research and Treatment
2023 .01
-
Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma
Blood Research
2016 .01
-
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
Cancer Research and Treatment
2016 .01
-
Prognostic significance of pretreatment lymphocyte percentage and age at diagnosis in patients with locally advanced cervical cancer treated with definite radiotherapy
Obstetrics & Gynecology Science
2019 .01
-
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study
Investigative and Clinical Urology
2020 .01
-
Genomics of diffuse large B cell lymphoma
Blood Research
2021 .01
-
Genomics of diffuse large B cell lymphoma
Blood Research
2021 .04
-
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Cancer Research and Treatment
2022 .04
-
The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
Journal of Yeungnam Medical Science
2023 .01
-
Prognostic Factors Affecting Disease-Free Survival and Overall Survival in T4 Colon Cancer
Annals of Coloproctology
2021 .08
-
The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients
Cancer Research and Treatment
2018 .01
-
Verification of the Correlation between Progression-free Survival and Overall Survival Considering Magnitudes of Survival Post-progression in the Treatment of Four Types of Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0